Business
New to The Street T.V. Announces its 255th and 256th Shows with Four Corporate Interviews, Airing on Fox Business Network, Tonight, Monday, October 25, 2021, at 10:30 PM P.T. and Tomorrow Night, Tuesday, October 26, 2021, at 10:30 PM PT
New to The Street T.V. Announces its 255th and 256th Shows with Four Corporate Interviews, Airing on Fox Business Network, Tonight, Monday, October 25, 2021, at 10:30 PM P.T. and Tomorrow Night, Tuesday, October 26, 2021, at 10:30 PM PT.
About this update from Epazz, Inc.
[{"type":"text","content":"\n NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FMW Media's New to The Street T.V. announces the broadcastings of its nationally syndicated shows tonight, Monday, October 25, 2021, at 10:30 PM PT and tomorrow, Tuesday night, October 26, 2021, at 10:30 PM PT on Fox Business Network. New to The Street’s 255th T.V. show, airing tonight, Monday, October 25, 2021, 10:30 PM P.T., on the Fox Business Network, features the following four (4) Companies and their businesses representatives: 1). PetVivo Holdings, Inc.'s (NASDAQ: PETV) interview, Mr. John Lai, CEO & President. 2). Epazz, Inc.'s (OTCPINK: EPAZ) interview, Mr. Mike Manahan, Vice-president Communications. 3). Rego Payments Architectures, Inc.'s. (OTCQB: RPMT) interviews, Mr. Dan Aptor, Head of Strategy, and Ms. Julie Jatlow, Partner, FUSE Digital Marketing firm. 4). Sekur's® (division of GlobeX Data, Ltd) \"SPECIAL SEGMENT\" interview, internet privacy expert Mr. Alain Ghiai, CEO. Airing tonight, Monday, October 25, 2021, the in-studio NASDAQ interview with Mr. John Lai, CEO & President, PetVivo Holdings, Inc. (NASDAQ: PETV). Talking with T.V.'s Host Jane King, Mr. Lai gives an overview of the Company's biomedical devices and its osteoarthritis treatment available to millions of dogs and horses. With about 17 new products in development at the Company, Mr. Lai gives examples of various products used for humans. PETV's vascular shunts show no clotting problems, a typical issue with current products in use. Another product development, their vascular stent, shows no thrombosis issues after 30-days of being applied, a specific problem related to existing products currently in the marketplace. At the recent veterinary conference in Las Vegas, John's says the Company's received very well. And at the Emerging Growth Conference, another attended venue allowed the Company to inform shareholders, potential shareholders, and industry professionals about the Spryng™ with OsteoCushion™ Technology injection. He explains how the US FDA views treatments and applications between humans and animals and the fundamental difference on a regulatory basis. He tells views to expect a feline product for cat pet owners, another multibillion-dollar market for the Spryng™ injection to gain recognition with cat owners as it has done with both dogs and horse owners. The...